Luis Pinheiro

Luis Pinheiro

Auto-generated profile, based on publicly available information

Luis Pinheiro

European Medicines Agency Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in JAMA Neurology
Verified
Journal Article
Closed access
PDF file
DMDaniel Morales
Daniel Morales
APAlexandra Pacurariu
Alexandra Pacurariu
JSJim Slattery
Jim Slattery
LPLuis Pinheiro
Luis Pinheiro
PMPatricia McGettigan
Patricia McGettigan
XKXavier Kurz
Xavier Kurz
Importance Peripheral neuropathy has been associated with systemic fluoroquinolone exposure, but risk has been poorly quantified. Objective To calculate relative and absolute risk estimates for the association of fluoroquinolone exposure with peripheral neuropathy and to examine how risk may be affected by timing of fluoroquinolone exposure and by other risk factors. Design, Setting, and Participants This nested case-control study used anonymized data from all patients routinely registered with general practices in The Health Improvement Network database, a large primary care population database in the United Kingdom, from January 1, 1999, to December 31, 2015. Data analyses were conducted January 8, 2018. The cohort consisted of 1 338 900 adults issued 1 or more prescriptions of fluoroquinolone (34.3%) or amoxicillin-clavulanate (65.7%) antibiotics. Adults with incident peripheral neuropathy were matched (on age, sex, general practice, and calendar time) with up to 4 controls by using incidence density sampling selected from a cohort prescribed oral fluoroquinolone or amoxicillin-clavulanate antibiotics. Incidence rate ratios of peripheral neuropathy were calculated for fluoroquinolone and for amoxicillin-clavulanate exposure and compared with nonexposure among patients without diabetes, with sensitivity analyses testing the consistency of the results. Population mean–adjusted rate differences were then estimated, including the number needed to harm for various durations of fluoroquinolone therapy. Exposures Current and cumulative exposure to oral fluoroquinolone or amoxicillin-clavulanate antibiotics. Main Outcomes and Measures Incident peripheral neuropathy cases recorded in electronic medical records. Results In total, 5357 patients with incident peripheral neuropathy (mean [SD] age, 65.6 [14.7] years; 2809 women [52.4%]) were matched to 17 285 controls (mean [SD] age, 64.4 [15.2] years; 9485 women [54.9%]) without diabetes. Current oral fluoroquinolone exposure was associated with an increased relative incidence of peripheral neuropathy compared with nonexposure (adjusted incident rate ratio, 1.47; 95% CI, 1.13-1.92). Risk increased by approximately 3% for each additional day of current fluoroquinolone exposure and persisted for up to 180 days following exposure. No significant increased risk was observed with oral amoxicillin-clavulanate exposure. The absolute risk with current oral fluoroquinolone exposure was 2.4 (95% CI, 1.8-3.1) per 10 000 patients per year of current use. The number needed to harm for a 10-day course was 152 083 patients (95% CI, 117 742-202 778) and was greatest among men and among patients older than 60 years. Conclusions and Relevance The results of the present study suggested that oral fluoroquinolone therapy was associated with an increased risk of incident peripheral neuropathy that may depend on the timing of the exposure and the cumulative dose. Health care professionals should consider these potential risks when prescribing fluoroquinolone antibiotics.

21 November 2018 in Clinical Drug Investigation
Verified
Journal Article
Open access
PDF file
DMDaniel R Morales
Daniel R Morales
JSJim Slattery
Jim Slattery
APAlexandra Pacurariu
Alexandra Pacurariu
LPLuis Pinheiro
Luis Pinheiro
PMPatricia McGettigan
Patricia McGettigan
XKXavier Kurz
Xavier Kurz
Background and Objective Tendon rupture can result from fluoroquinolone exposure. The objective of this study was to quantify relative and absolute risk and determine how risk is affected by timing of exposure. Methods The UK Health Improvement Network primary care database was used to perform a nested case–control study measuring the association between fluoroquinolone exposure and tendon rupture. Adults with tendon rupture were matched on age, sex, general practice and calendar time to four controls selected from a cohort prescribed systemic fluoroquinolone or co-amoxiclav antibiotics. The relative and absolute risk of tendon rupture with fluoroquinolone exposure was calculated. Results Current fluoroquinolone exposure was associated with an increased risk of any tendon rupture (adjusted incidence rate ratio [aIRR] 1.61, 95% CI 1.25–2.09) and Achilles tendon rupture (aIRR 3.14, 95% CI 2.11–4.65) that persisted for 60 days. Risk increased with cumulative exposure and was greatest when co-prescribed with oral corticosteroids (aIRR 19.36, 95% CI 7.78–48.19 for Achilles tendon rupture). The adjusted rate difference (aRD) with fluoroquinolone exposure was 2.9 and 2.1 per 10,000 patients for any and Achilles tendon rupture, respectively, and was greatest in people aged ≥ 60 years prescribed concomitant oral corticosteroid therapy (aDR 19.6 for any tendon and 6.6 Achilles tendon rupture per 10,000). No association was seen with co-amoxiclav or statin exposure, or with biceps or other tendon ruptures. Conclusions Risk of tendon rupture with fluoroquinolones depends on timing, cumulative dose and concomitant exposure to oral corticosteroids. Absolute risk significantly varied by age and concomitant corticosteroid exposure, affecting elderly patients the greatest.

21 May 2018 in Drug Safety
Verified
Journal Article
Closed access
PDF file
JSJim Slattery
Jim Slattery
DMDaniel Morales
Daniel Morales
LPLuis Pinheiro
Luis Pinheiro
XKXavier Kurz
Xavier Kurz

12 November 2024 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
FDFrancesco Dernie
Francesco Dernie
GCGeorge Corby
George Corby
ARAbigail Robinson
Abigail Robinson
JBJames Bezer
James Bezer
NMNuria Mercade‐Besora
Nuria Mercade‐Besora
APAlbert Prats‐Uribe
Albert Prats‐Uribe
Purpose: The generation of representative disease phenotypes is important for ensuring the reliability of the findings of observational studies. The aim of this manuscript is to outline a reproducible framework for reliable and traceable phenotype generation based on real world data for use in the Data Analysis and Real‐World Interrogation Network (DARWIN EU). We illustrate the use of this framework by generating phenotypes for two diseases: pancreatic cancer and systemic lupus erythematosus (SLE).Methods: The phenotyping process involves a 14‐steps process based on a standard operating procedure co‐created by the DARWIN EU Coordination Centre in collaboration with the European Medicines Agency. A number of bespoke R packages were utilised to generate and review codelists for two phenotypes based on real world data mapped to the OMOP Common Data Model.Results: Codelists were generated for both pancreatic cancer and SLE, and cohorts were generated in six OMOP‐mapped databases. Diagnostic checks were performed, which showed these cohorts had broadly similar incidence and prevalence figures to previously published literature, despite significant inter‐database variability. Co‐occurrent symptoms, conditions, and medication use were in keeping with pre‐specified clinical descriptions based on previous knowledge.Conclusions: Our detailed phenotyping process makes use of bespoke tools and allows for comprehensive codelist generation and review, as well as large‐scale exploration of the characteristics of the resulting cohorts. Wider use of structured and reproducible phenotyping methods will be important in ensuring the reliability of observational studies for regulatory purposes.

24 August 2018 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
DMDaniel R. Morales
Daniel R. Morales
JSJim Slattery
Jim Slattery
LPLuis Pinheiro
Luis Pinheiro
XKXavier Kurz
Xavier Kurz
KHKarin Hedenmalm
Karin Hedenmalm

8 September 2022 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
LPLuis Correia Pinheiro
Luis Correia Pinheiro
XKXavier Kurz
Xavier Kurz